These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 10602499)

  • 1. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6.
    Pim D; Banks L
    Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth.
    Pim D; Massimi P; Banks L
    Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
    Mantovani F; Banks L
    Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells.
    Pim D; Storey A; Thomas M; Massimi P; Banks L
    Oncogene; 1994 Jul; 9(7):1869-76. PubMed ID: 8208532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
    Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
    Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation.
    Thomas M; Matlashewski G; Pim D; Banks L
    Oncogene; 1996 Jul; 13(2):265-73. PubMed ID: 8710365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
    Mansur CP; Marcus B; Dalal S; Androphy EJ
    Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction between the HPV-16 E2 transcriptional activator and p53.
    Massimi P; Pim D; Bertoli C; Bouvard V; Banks L
    Oncogene; 1999 Dec; 18(54):7748-54. PubMed ID: 10618715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
    López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
    Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
    Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
    Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the E6-p53 interaction in the molecular pathogenesis of HPV.
    Thomas M; Pim D; Banks L
    Oncogene; 1999 Dec; 18(53):7690-700. PubMed ID: 10618709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells.
    Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL
    Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro.
    Hampson L; Kitchener HC; Hampson IN
    Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products.
    Münger K; Scheffner M; Huibregtse JM; Howley PM
    Cancer Surv; 1992; 12():197-217. PubMed ID: 1322242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of serum- and calcium-induced terminal differentiation of human keratinocytes by HPV 16 E6: study of the association with p53 degradation, inhibition of p53 transactivation, and binding to E6BP.
    Sherman L; Itzhaki H; Jackman A; Chen JJ; Koval D; Schlegel R
    Virology; 2002 Jan; 292(2):309-20. PubMed ID: 11878933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
    Thomas M; Massimi P; Jenkins J; Banks L
    Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
    Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
    Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational analysis of human papillomavirus type 16 E6 protein: transforming function for human cells and degradation of p53 in vitro.
    Nakagawa S; Watanabe S; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Virology; 1995 Oct; 212(2):535-42. PubMed ID: 7571423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
    Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
    Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
    Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
    J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.